IntelliPharmaCeutics International (IPCI) announced after the bell Monday that the FDA has granted final approval of the Company's dexmethylphenidate hydrochloride extended-release capsules for the 15 and 30 mg strengths.
IntelliPharmaCeutics International gapped open dramatically higher Tuesday and is now up 1.78 at $3.67 on the highest volume of the year. The stock has surged to a new high for the year.
For comments and feedback: editorial@rttnews.com